compelling

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress

October 19, 2025 10:00 ET  | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…

2 months ago